What is preeclampsia

What It Is

Preeclampsia is a multifactorial pregnancy disorder defined by the new onset of hypertension (blood pressure ≥140/90 mmHg) and proteinuria or other evidence of maternal end-organ dysfunction after 20 weeks of gestation in a previously normotensive woman. The condition represents a complex interaction between placental insufficiency, maternal cardiovascular dysfunction, and systemic inflammation. It is responsible for approximately 5-7% of all pregnancies and accounts for significant maternal and perinatal morbidity and mortality worldwide. The pathophysiology involves inadequate remodeling of uterine spiral arteries, leading to reduced placental perfusion and the release of harmful factors into maternal circulation.

The historical understanding of preeclampsia dates back to ancient Greece, where Hippocrates first documented cases of eclamptic seizures in pregnant women around 460 BCE. In the 18th and 19th centuries, European obstetricians began systematically describing the syndrome, though its mechanisms remained mysterious until the 20th century. The term "preeclampsia" was officially coined in the early 1900s to describe the condition preceding eclamptic seizures. Modern understanding accelerated dramatically in the 1990s and 2000s with the discovery of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) dysregulation as central pathogenic mechanisms.

Preeclampsia exists on a spectrum with several recognized classifications based on severity and timing of onset. Early-onset preeclampsia occurs before 34 weeks of gestation and typically represents more severe disease with worse maternal and fetal outcomes. Late-onset preeclampsia develops at or after 34 weeks and generally has better prognosis, though maternal complications still require careful management. Preeclampsia with severe features includes blood pressure ≥160/110 mmHg, platelet count <100,000/μL, liver enzyme elevation, pulmonary edema, or severe headache with visual disturbances.

How It Works

The pathogenesis of preeclampsia begins with abnormal placentation, where cytotrophoblastic cells fail to adequately invade the uterine spiral arteries and transform them into low-resistance vessels. This incomplete vascular remodeling results in chronic placental underperfusion and hypoxia, triggering the release of antiangiogenic factors, particularly soluble fms-like tyrosine kinase-1 (sFlt-1) and endoglin. These factors bind and sequester vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their normal endothelial cell signaling. The subsequent widespread endothelial dysfunction causes vasoconstriction, increased capillary permeability, platelet activation, and activation of the coagulation cascade throughout maternal tissues.

A practical example of preeclampsia monitoring occurs in routine prenatal care at institutions like Massachusetts General Hospital and Mayo Clinic, where standardized blood pressure protocols and urine protein assessments are performed at each visit. At approximately 36 weeks gestation, a pregnant patient named Maria presents with a blood pressure of 145/95 mmHg (up from her baseline of 120/70) and 2+ proteinuria on urinalysis, prompting suspicion for preeclampsia. Her serum biomarkers reveal an sFlt-1/PlGF ratio of 85 (normal <38), confirming placental dysfunction. Additional lab work shows mild thrombocytopenia and elevated liver enzymes, indicating progression to preeclampsia with severe features.

The practical implementation of preeclampsia management follows a stepwise approach beginning with confirmed diagnosis through objective measurements and maternal symptom assessment. Once preeclampsia is diagnosed, delivery is the definitive cure, though timing depends on gestational age and severity to balance maternal safety against neonatal prematurity risks. For severe preeclampsia at term (≥37 weeks), immediate delivery by induction of labor or cesarean section is recommended. For preeclampsia <34 weeks, expectant management with magnesium sulfate for seizure prophylaxis, corticosteroids for fetal lung maturity, and close maternal and fetal monitoring represents standard care.

Why It Matters

Preeclampsia remains a leading cause of maternal mortality and morbidity in both developed and developing nations, accounting for approximately 76,000 maternal deaths annually worldwide. In the United States, preeclampsia complications (including eclampsia and HELLP syndrome) contribute to approximately 15-20% of pregnancy-related deaths. The condition increases risks for placental abruption, disseminated intravascular coagulation (DIC), acute kidney injury, pulmonary edema, cerebral hemorrhage, and maternal death. Beyond the acute pregnancy period, women with a history of preeclampsia face a 4-fold increased risk of chronic hypertension and 2-fold increased risk of cardiovascular disease within the subsequent decade.

Across diverse clinical settings including major academic medical centers, community hospitals, and rural clinics, preeclampsia detection and management protocols significantly impact patient outcomes. Institutions implementing standardized screening algorithms, such as those developed by the American College of Obstetricians and Gynecologists (ACOG) and the National Institute for Health and Care Excellence (NICE), report improved early detection and reduced maternal complications. Home blood pressure monitoring programs integrated with telemedicine have proven effective in resource-limited settings, reducing emergency department visits and unnecessary hospitalizations. Multidisciplinary care teams involving maternal-fetal medicine specialists, anesthesiologists, and neonatologists optimize outcomes for high-risk pregnancies complicated by severe preeclampsia.

Future developments in preeclampsia prevention and management are emerging through advanced biomarker research and precision medicine approaches. Novel first-trimester screening strategies combining maternal serum biomarkers (PAPP-A, PlGF, sFlt-1), uterine artery Doppler findings, and maternal clinical risk factors now achieve detection rates exceeding 90% for early-onset preeclampsia. Aspirin prophylaxis initiated in the first trimester in high-risk women reduces early-onset preeclampsia incidence by approximately 60% according to major clinical trials. Ongoing research into novel therapeutic interventions targeting the PlGF/sFlt-1 imbalance, including recombinant PlGF therapy and sFlt-1 antagonists, offers promise for future disease modification beyond delivery.

Common Misconceptions

Myth 1: "Preeclampsia only affects women with pre-existing hypertension." This is false; preeclampsia can develop in completely healthy, normotensive women with no prior cardiovascular disease. Approximately 30-40% of women with preeclampsia have no identifiable risk factors before pregnancy, classifying them as low-risk pregnancies. Risk factors do increase probability (obesity, diabetes, chronic hypertension, prior preeclampsia), but their absence does not provide immunity. Even the healthiest multiparous women can develop new-onset preeclampsia, often presenting as a surprise to both patients and clinicians who viewed the pregnancy as low-risk.

Myth 2: "High blood pressure readings in pregnancy are always just 'gestational hypertension' and not serious." This misunderstanding delays critical diagnosis; preeclampsia specifically requires proteinuria or other signs of end-organ dysfunction alongside elevated blood pressure. Gestational hypertension (elevated BP without proteinuria) is qualitatively different from preeclampsia and carries substantially lower risks for adverse outcomes. A single elevated blood pressure reading should never be dismissed, as confirmed preeclampsia requires two readings ≥140/90 mmHg at least 4 hours apart. The distinction between gestational hypertension and preeclampsia is clinically crucial, as preeclampsia mandates closer monitoring and often delivery while gestational hypertension may allow conservative management.

Myth 3: "Preeclampsia symptoms are always obvious and easily recognizable." Many women with preeclampsia remain asymptomatic or experience only mild, nonspecific symptoms that mimic normal pregnancy changes. Headache, upper quadrant pain, visual disturbances, and shortness of breath are concerning features suggesting severe disease, but many women with confirmed preeclampsia report feeling perfectly well during routine screening. This asymptomatic presentation makes universal objective screening essential, as solely relying on patient-reported symptoms would miss many cases of dangerous disease. The lack of obvious symptoms should never reassure clinicians; all pregnant women require regular blood pressure monitoring and urine screening for proteinuria regardless of how they feel.